Is ADARx Pharmaceuticals, Inc. (ADRX) Overvalued?
We dive into why ADARx Pharmaceuticals, Inc. (ADRX) could be considered overvalued on 2026-11-19, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Tudor Pop
Rosalio Madrigal
Jenna Brashear
Tudor Pop
| Share Statistics | ADRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,412.2 | $203.5 | 51% |
|
| Shares Out (Mil) | 16.1 | 55.2 | 27% |
|
| Institutional Ownership | 81.1% | 93.3% | 49% |
|
| Float (Mil) | 40.0 | 40.4 | 41% |
|
| Beta | na | 1.05 | na |
|
| Avg Daily Volume (000s) | 602 | 569 | 61% |
|
| Price Change (52-week) |
na | 38.8% | na |
|
| Growth | ADRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.7%) | na |
|
| EPS (5yr) | na | 15.4% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.392) | ($2.030) | ($1.540) | |
| Month Ago EPS | ($0.379) | ($1.679) | ($1.513) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (77.5%) | (73.1%) | (76.9%) | |
| Financials | ADRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $40 | 7% |
|
| Net Income (TTM) (Mil) | ($98) | ($44) | 11% |
|
| EPS (TTM) | ($8.641) | ($1.400) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($90) | ($35) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $498 | $-0 | 91% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | $531 | $142 | 35% |
|
| Valuation | ADRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.37 | 1.96 | 64% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ADRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (21.1%) | (47.0%) | 19% |
|
| ROE | (34.2%) | (51.8%) | 19% |
|
| Liabilities to Assets | 38.2% | 29.6% | 29% |
|
| F-Score | 1 | 3 | na |
|
ADARx Pharmaceuticals, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors